HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

plozalizumab

a human CCR2 blocking antibody

Also Known As:

HU-1D9; HU1D9; MLN-1202; MLN1202

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Davidson, Michael: 1 article (03/2011)
2.	Donaldson, Debra: 1 article (03/2011)
3.	Gilbert, Jim: 1 article (03/2011)
4.	Hu, Mingxiu: 1 article (03/2011)
5.	Lee, Yih: 1 article (03/2011)
6.	Lekstrom-Himes, Julie: 1 article (03/2011)
7.	MLN1202 Study Group: 1 article (03/2011)
8.	Wyant, Tim: 1 article (03/2011)
9.	Xu, Jing: 1 article (03/2011)

Related Diseases

1.	Inflammation (Inflammations) 03/15/2011 - "The aim of this randomized, double-blind, placebo-controlled study was to measure reductions in circulating levels of high-sensitivity C-reactive protein, an established biomarker of inflammation associated with coronary artery disease, on MLN1202 treatment in patients at risk for atherosclerotic cardiovascular disease (≥2 risk factors for atherosclerotic cardiovascular disease and circulating high-sensitivity C-reactive protein >3 mg/L). "
2.	Coronary Artery Disease (Coronary Atherosclerosis) 03/15/2011 - "The aim of this randomized, double-blind, placebo-controlled study was to measure reductions in circulating levels of high-sensitivity C-reactive protein, an established biomarker of inflammation associated with coronary artery disease, on MLN1202 treatment in patients at risk for atherosclerotic cardiovascular disease (≥2 risk factors for atherosclerotic cardiovascular disease and circulating high-sensitivity C-reactive protein >3 mg/L). "
3.	Cardiovascular Diseases (Cardiovascular Disease) 03/15/2011 - "The aim of this randomized, double-blind, placebo-controlled study was to measure reductions in circulating levels of high-sensitivity C-reactive protein, an established biomarker of inflammation associated with coronary artery disease, on MLN1202 treatment in patients at risk for atherosclerotic cardiovascular disease (≥2 risk factors for atherosclerotic cardiovascular disease and circulating high-sensitivity C-reactive protein >3 mg/L). "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	C-Reactive Protein